Novo Nordisk’s Semaglutide Tops Madrigal’s Rezdiffra In NASH

Greater Combined Effect Seen In Phase III Trials

 
• By Joseph Haas
  
Novo Nordisk presented more data for semaglutide in NASH at AASLD (Shutterstock)

More from Conferences

More from Alimentary/Metabolic